Viewing Study NCT06042569


Ignite Creation Date: 2025-12-24 @ 10:50 PM
Ignite Modification Date: 2026-04-25 @ 4:07 PM
Study NCT ID: NCT06042569
Status: RECRUITING
Last Update Posted: 2025-10-09
First Post: 2023-09-07
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Sponsor: City of Hope Medical Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Anatomic Stage I Breast Cancer AJCC v8 View
None Anatomic Stage II Breast Cancer AJCC v8 View
None Anatomic Stage III Breast Cancer AJCC v8 View
None HER2-Negative Breast Carcinoma View
Keywords: